EORTC literature review highlights methodology issues in immuno oncology

In a recent paper published in Annals of Translational Medicine the EORTC highlights the need to develop new clinical research methodologies to evaluate immune-oncology anti cancer agents. While immune strategies are taking a central role in the spectrum of therapeutic options, current methodologies to define optimal dose and classical activity end-points may not be adapted to the mode of operation of these innovative therapies.

“The lack of fundamental information such as dose and end-points may be an impediment in appropriately and safely integrating new immune therapies in combination with other agents and therapeutic modalities,” alerts first author Dr Jessica Menis, Clinical Research Physician at the EORTC.

“The absence of a solid predictive biomarker and generally accepted standard assay makes it impossible to define an optimal candidate patient population. Duplication of diagnostic solutions will impact the functioning of pathology departments,” emphasizes Dr Saskia Litière, Biostatistician at the EORTC.

Although the safety profile of immune therapies seems to be relatively safe, “there is no mechanism to ensure long-term follow-up monitoring of side effects at a time when real life effectiveness is a crucial aspect of drug development, ” according to Dr Konstantinos Tryfonidis, Clinical Research Physician at EORTC.

“The next hurdle is the economic challenge of immuno-oncology. We urgently need studies addressing schedule and dose optimization, as well as refining patient populations who truly benefit from treatment,” concludes Dr Vassilis Golfinopoulos, Medical Director at EORTC.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023